Targeting chondroitinase ABC to axons enhances the ability of chondroitinase to promote neurite outgrowth and sprouting.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 18 02 2019
accepted: 18 08 2019
entrez: 22 1 2020
pubmed: 22 1 2020
medline: 2 4 2020
Statut: epublish

Résumé

There is currently no effective treatment for promoting regeneration of injured nerves in patients who have sustained injury to the central nervous system such as spinal cord injury. Chondroitinase ABC is an enzyme, which promotes neurite outgrowth and regeneration. It has shown considerable promise as a therapy for these conditions. The aim of the study is to determine if targeting chondroitinase ABC expression to the neuronal axon can further enhance its ability to promote axon outgrowth. Long-distance axon regeneration has not yet been achieved, and would be a significant step in attaining functional recovery following spinal cord injury. To investigate this, neuronal cultures were transfected with constructs encoding axon-targeted chondroitinase, non-targeted chondroitinase or GFP, and the effects on neuron outgrowth and sprouting determined on substrates either permissive or inhibitory to neuron regeneration. The mechanisms underlying the observed effects were also explored. Targeting chondroitinase to the neuronal axon markedly enhances its ability to promote neurite outgrowth. The increase in neurite length is associated with an upregulation of β-integrin staining at the axonal cell surface. Staining for phosphofocal adhesion kinase, is also increased, indicating that the β-integrins are in an activated state. Expression of chondroitinase within the neurons also resulted in a decrease in expression of PTEN and RhoA, molecules which present a block to neurite outgrowth, thus identifying two of the pathways by which ChABC promotes neurite outgrowth. The novel finding that targeting ChABC to the axon significantly enhances its ability to promote neurite extension, suggests that this may be an effective way of promoting long-distance axon regeneration following spinal cord injury. It could also potentially improve its efficacy in the treatment of other pathologies, where it has been shown to promote recovery, such as myocardial infarction, stroke and Parkinson's disease.

Sections du résumé

BACKGROUND
There is currently no effective treatment for promoting regeneration of injured nerves in patients who have sustained injury to the central nervous system such as spinal cord injury. Chondroitinase ABC is an enzyme, which promotes neurite outgrowth and regeneration. It has shown considerable promise as a therapy for these conditions. The aim of the study is to determine if targeting chondroitinase ABC expression to the neuronal axon can further enhance its ability to promote axon outgrowth. Long-distance axon regeneration has not yet been achieved, and would be a significant step in attaining functional recovery following spinal cord injury.
METHODOLOGY/PRINCIPAL FINDINGS
To investigate this, neuronal cultures were transfected with constructs encoding axon-targeted chondroitinase, non-targeted chondroitinase or GFP, and the effects on neuron outgrowth and sprouting determined on substrates either permissive or inhibitory to neuron regeneration. The mechanisms underlying the observed effects were also explored. Targeting chondroitinase to the neuronal axon markedly enhances its ability to promote neurite outgrowth. The increase in neurite length is associated with an upregulation of β-integrin staining at the axonal cell surface. Staining for phosphofocal adhesion kinase, is also increased, indicating that the β-integrins are in an activated state. Expression of chondroitinase within the neurons also resulted in a decrease in expression of PTEN and RhoA, molecules which present a block to neurite outgrowth, thus identifying two of the pathways by which ChABC promotes neurite outgrowth.
CONCLUSIONS / SIGNIFICANCE
The novel finding that targeting ChABC to the axon significantly enhances its ability to promote neurite extension, suggests that this may be an effective way of promoting long-distance axon regeneration following spinal cord injury. It could also potentially improve its efficacy in the treatment of other pathologies, where it has been shown to promote recovery, such as myocardial infarction, stroke and Parkinson's disease.

Identifiants

pubmed: 31961897
doi: 10.1371/journal.pone.0221851
pii: PONE-D-19-04850
pmc: PMC6974052
doi:

Substances chimiques

PTEN Phosphohydrolase EC 3.1.3.67
rhoA GTP-Binding Protein EC 3.6.5.2
Chondroitin ABC Lyase EC 4.2.2.20

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0221851

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R004463/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : RG45123
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2017 Nov 9;12(11):e0186759
pubmed: 29121057
Cell Motil Cytoskeleton. 2003 Jun;55(2):77-96
pubmed: 12740870
J Neurosci. 2009 Apr 29;29(17):5546-57
pubmed: 19403822
Nat Neurosci. 2009 Sep;12(9):1145-51
pubmed: 19668200
Gene Ther. 2012 Sep;19(9):947-55
pubmed: 22278412
Nat Rev Neurosci. 2004 Feb;5(2):146-56
pubmed: 14735117
Cell Tissue Res. 2012 Jul;349(1):119-32
pubmed: 22350947
J Tissue Eng Regen Med. 2017 Mar;11(3):733-742
pubmed: 25424415
Cereb Cortex. 2015 Jan;25(1):202-12
pubmed: 23960208
Exp Neurol. 2015 May;267:64-77
pubmed: 25725355
Methods. 2015 May;77-78:63-8
pubmed: 25747336
J Alzheimers Dis. 2010;20(4):1069-82
pubmed: 20413890
J Neurosci. 2013 Apr 24;33(17):7175-83
pubmed: 23616527
J Neurosci. 1998 Jan 1;18(1):174-83
pubmed: 9412498
Exp Neurol. 2015 Apr;266:147-60
pubmed: 25704959
Exp Neurol. 1990 Jul;109(1):111-30
pubmed: 2141574
J Neurosci. 2012 Dec 12;32(50):18009-17, 18017a
pubmed: 23238717
J Neurosci. 2012 Oct 10;32(41):14442-7
pubmed: 23055514
Nature. 1996 Apr 11;380(6574):538-40
pubmed: 8606775
J Neurosci. 2010 Oct 6;30(40):13291-304
pubmed: 20926655
Prog Brain Res. 2002;137:313-32
pubmed: 12440375
Mol Cell Neurosci. 2011 Jan;46(1):235-44
pubmed: 20869442
J Neurosci. 2014 Apr 2;34(14):4822-36
pubmed: 24695702
Sci Rep. 2018 Jul 11;8(1):10452
pubmed: 29993013
Brain Res. 2014 Jan 16;1543:324-33
pubmed: 24326094
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16532-7
pubmed: 17062754
Nat Neurosci. 2010 Sep;13(9):1075-81
pubmed: 20694004
J Neurosci. 2006 Apr 19;26(16):4406-14
pubmed: 16624960
J Neurotrauma. 2012 Jul 1;29(10):1850-63
pubmed: 22497349
ACS Chem Biol. 2006 Dec 15;1(12):780-90
pubmed: 17240976
Dev Cell. 2010 Apr 20;18(4):533-43
pubmed: 20412769
J Cell Sci. 2008 Sep 15;121(Pt 18):3083-91
pubmed: 18768934
J Biotechnol. 2010 Jan 15;145(2):103-10
pubmed: 19900493
J Neurosci. 2011 Apr 27;31(17):6289-95
pubmed: 21525268
J Neurosci. 2014 Nov 12;34(46):15347-55
pubmed: 25392502
J Neurosci. 1986 Mar;6(3):714-22
pubmed: 3514816
Nature. 2002 Apr 11;416(6881):636-40
pubmed: 11948352
J Neurosci Methods. 2011 Sep 30;201(1):228-38
pubmed: 21855577

Auteurs

Priscilla Day (P)

Department of Physiology Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom.

Nuno Alves (N)

John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge, United Kingdom.

Esther Daniell (E)

Department of Physiology Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom.

Debayan Dasgupta (D)

Department of Physiology Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom.

Rosalie Ogborne (R)

Department of Physiology Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom.

Ashley Steeper (A)

Department of Physiology Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom.

Mansoor Raza (M)

Department of Physiology Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom.

Clare Ellis (C)

Department of Physiology Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom.

James Fawcett (J)

John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge, United Kingdom.

Roger Keynes (R)

Department of Physiology Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom.

Elizabeth Muir (E)

Department of Physiology Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH